Dr. Mohammad Jahanzeb

  • Medical Oncologist
  • Spoken languages English


Career Positions

Current position(s)

  • GenesisCare - Chief Medical Oncology Scientific and Strategic Advisor, Boca Raton, FL

Past position(s)

  • Sylvester Comprehensive Cancer Center - Professor of Clinical Medicine, Hematology-Oncology, Deerfield Beach, FL
  • Sylvester Comprehensive Cancer Center - Medical Director, Deerfield Beach, FL
  • Sylvester Comprehensive Cancer Center - Volunteer Assistant Professor, Deerfield Beach, FL
  • Lynn Comprehensive Cancer Center - Medical Director, West, Boca Raton, FL
  • University of Tennessee College of Medicine - Chief -·Division of Hematology/Oncology, Memphis, TN
  • University of Tennessee - Fellowship Program Director Hematology Oncology Division, Memphis, TN



  • King Edward Medical College, University of Punjab, MD, Medicine, Lahore, Pakistan


  • The University of Connecticut, Internal Medicine, Mansfield, CT


  • Washington University in St. Louis, Hematology and Oncology, St. Louis, MO

Expertise And Interests


  • Cancers of the breast and lung.


Awards and honors

  • Castle Connolly Top Doctors in America 2010-2016Best Doctors in America 2007-2008, 2011Castle Connolly Medical Best Doctors in America 2006Gold Medal Award KEMCAANA 2006NCCN Board of Producers Award 2008Silver Medal in Final Professional M.B.B.S. (MD)Nati


  • Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review.

Clinical studies

Primary Objective • To assess whether ALK kinase domain mutations (G1202/C1156Y /I1171/L1196/ V1180/ F1174/ compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. • To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients • To evaluate objective responses of patients with specific genetic alterations (ALKL1198F/MET double mutation or high-level MET gene amplification) treated with crizotinib.

View Study

Mohammad Jahanzeb's Reviews


based on 85 Ratings 26 Comments


Easier directions to get there


I would have liked to have more conversation. To my recollection there was a lot of people around and not much said that was about my feelings towards my future treatment.


Staff should be mindful of how they express their frustrations to other coworkers about their colleagues. Patients in the exam rooms can hear what is being said.


Nothing. As a new patient, I am completely satisfied with my first visit.

Read More

Ratings and Comments Powered by NRC Health